Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

UK Biotech: A 10 Year Horizon


EvaluatePharma World Preview 2015, Outlook to 2020

UK Biotech: A 10 Year Horizon

This analysis of the UK biotech industry is the result of a joint collaboration between the BIA and Evaluate to examine the performance of the UK biotech industry over the past decade. The report provides a detailed view of the industry between 2005 and 2014 and highlights trends in M&A, drug approvals, venture financing and IPOs.

Over the past 10 years, the UK's biotech sector has outperformed other European countries, raising an impressive £923.7 million via IPOs and $2.4 billion in venture capital. The rise in optimism has been most evident in 2014 with the momentum continuing into 2015. 2014 was a big turning point for the UK biotech sector. In this year alone, on the public market, nine companies listed, raising a total of £408 million, almost half of the total IPO haul for the past decade.

UK Biotech: A 10 Year Horizon highlights:

  • Strong confidence in UK market is reflected in recent IPO activity reaching £408 million in 2014, with a further two IPOs in 2015
  • Good stock market performance of new entrants, including 247% share gain by 4D Pharma since its IPO, helping to highlight the benefits of investing in the sector
  • Increase in exits (via IPO and trade sales) have created a 10 year record in venture funding: investment in 2014 is up 71% to $430 million (2013: $251 million)
  • Fewer larger financing deals took place in 2014, indicating a change in investment style
  • Venture capital seed funding declined dramatically to 1 in 2014; although the $20 million raised equalled almost the total of the last four years combined
  • UK is holding its own against the US and outperforming Europe in the past five years for venture funding

Press Release

Download UK Biotech: A 10 Year Horizon